Lin Chen

Dr. Lin Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CXChengjie Xiong
Chengjie Xiong
LHLihong Huang
Lihong Huang
HKHedan Kou
Hedan Kou
CWChenwei Wang
Chenwei Wang
XZXiaomin Zeng
Xiaomin Zeng
LCLin Chen
Lin Chen
Background: E6 and E7 oncoproteins are considered ideal antigens of T cell therapy for human papillomavirus (HPV)-related cancers. However, little is known about the epitopes of E6 and E7 presented by HLA-A*11:01, one of the most prevalent HLA types globally, especially in Asia. Methods: We combined in silico and experimental approaches to identify endogenously processed HLA-A*11:01-restricted epitopes of HPV16 E6 and E7. The identified epitopes were then used to screen available T cell receptors (TCRs) from healthy donors through in vitro stimulation of peripheral blood mononuclear cells (PBMCs). Results: E693-101 (TTLEQQYNK, TTL) and E789-97 (IVCPICSQK, IVC), two novel HLA-A*11:01-restricted T cell epitopes of HPV16, were identified to be endogenously presented on tumor cells. TTL- and IVC-specific TCRs were isolated from 11 healthy donors through in vitro stimulation of PBMC. The key TTL and IVC residues involved in TCR-pMHC interactions were mapped, and the consensus sequence was “xxLEQxYNK” and “xVxPIxxxK.” The TTL- and IVC-specific TCRs with high functional avidity were used to generate TCR-engineered T cells, specifically recognizing and killing corresponding tumor cell lines in vitro and in vivo. In addition, TTL and IVC-specific TCR-T cells also recognized and killed HPV16+ patient-derived organoids. Conclusions: The HLA-A*11:01-restricted HPV16 E6/E7 epitopes and TCRs identified in this study may provide a new strategy for HPV-related cancer immunotherapy in HLA-A*11:01+ patients.

1 June 2020 in Annals of Blood
Verified
Journal Article
Open access
PDF file
CWChenwei Wang
Chenwei Wang
CXChengjie Xiong
Chengjie Xiong
YHYung-Chun Hsu
Yung-Chun Hsu
XWXiaoling Wang
Xiaoling Wang
LCLin Chen
Lin Chen
Cancer immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies and tumor vaccines, has recently shown impressive results in the treatment of multiple cancers. The key step shared by these therapies requires T cells to recognize the specific peptides presented by the human leukocyte antigens (HLAs) on the membranes of tumor cells and subsequently kick off an immune response. HLA class I molecules exist in most human cell types and can interact with T cell receptors (TCRs) to activate T cells, which are important molecules that induce adaptive immune responses. In recent years, research on cell therapy has mainly focused on CD8+ T cell therapy, such as tumor-infiltrating lymphocytes (TILs) therapy and TCR-engineered T cells (TCR-Ts) therapy, which are both HLA-dependent immunotherapy. However, tumor cells may escape T cell attack through HLA downregulation, which limits HLA-dependent immunotherapy to some extent. Thus, HLA-independent immune cell therapies such as chimeric antigen receptor T-cell therapy, natural killer cell therapy and CD4+ T cell therapy shed new light on this issue. In this review, we summarized the mechanisms of antigen presentation by HLAs, the latest progress of HLA-presented peptides identification, and the current status of HLA-dependent and -independent adoptive immunotherapies.

27 February 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CWChenwei Wang
Chenwei Wang
JCJiewen Chen
Jiewen Chen
JLJingyao Li
Jingyao Li
ZXZhihong Xu
Zhihong Xu
LHLihong Huang
Lihong Huang
LCLin Chen
Lin Chen
Adoptive transfer of T cell receptor–engineered T cells (TCR-T) is a promising strategy for immunotherapy against solid tumors. However, the potential of CD4 + T cells in mediating tumor regression has been neglected. Nasopharyngeal cancer is consistently associated with EBV. Here, to evaluate the therapeutic potential of CD4 TCR-T in nasopharyngeal cancer, we screened for CD4 TCRs recognizing EBV nuclear antigen 1 (EBNA1) presented by HLA-DP5. Using mass spectrometry, we identified EBNA1 567–581 , a peptide naturally processed and presented by HLA-DP5. We isolated TCR135, a CD4 TCR with high functional avidity, that can function in both CD4 + and CD8 + T cells and recognizes HLA-DP5–restricted EBNA1 567–581 . TCR135-transduced T cells functioned in two ways: directly killing HLA-DP5 + EBNA1 + tumor cells after recognizing EBNA1 presented by tumor cells and indirectly killing HLA-DP5–negative tumor cells after recognizing EBNA1 presented by antigen-presenting cells. TCR135-transduced T cells preferentially infiltrated into the tumor microenvironment and significantly inhibited tumor growth in xenograft nasopharyngeal tumor models. Additionally, we found that 62% of nasopharyngeal cancer patients showed 50%–100% expression of HLA-DP on tumor cells, indicating that nasopharyngeal cancer is well suited for CD4 TCR-T therapy. These findings suggest that TCR135 may provide a new strategy for EBV-related nasopharyngeal cancer immunotherapy in HLA-DP5 + patients.

9 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
LWLinlin Wang
Linlin Wang
CDChangqi Du
Changqi Du
BJBing Jiang
Bing Jiang
LCLin Chen
Lin Chen
ZWZibing Wang
Zibing Wang
Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes.

22 September 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZYZhengning Yang
Zhengning Yang
ZMZhongxuan Meng
Zhongxuan Meng
SLShangyuan Liu
Shangyuan Liu
YCYuxin Chen
Yuxin Chen
XGXuhong Gan
Xuhong Gan
XWXiaoling Wang
Xiaoling Wang
Background: Nonsense-mediated messenger RNA decay (NMD) is a highly conserved surveillance system that degrades mRNAs with premature termination codons (PTCs), and regulates the mRNA quantity. Cancer cells hijack NMD to compensate for the imbalanced DNA levels and modulate their antigenicity. We identified the LTO1/YAE1 complex as NMD factors regulating ribosome biogenesis. Our study aimed to investigate their roles in modulating NMD and major histocompatibility complex class I (MHC-I) antigen presentation, which is vital for cancer immunotherapy. Methods: Clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-associated protein 9 (Cas9)-mediated gene knockouts, overexpression, and mutational analysis were used to explore the role of LTO1 and YAE1 in NMD and MHC-I expression across various tumor cell lines, assayed by fluorescent reporter-based assays, fluorescence-activated cell sorting analysis, reverse transcription-quantitative PCR, mRNA decay assay, and polysome profiling. Transcriptomic analyses were used to assess the expression of LTO1/YAE1 and their correlation with MHC-I molecules in human cancers. T cell receptor (TCR)-T cells and tumor cells coculture were employed to monitor the effect of LTO1 and YAE1 loss on T cell activation. Iron chelators were further tested as NMD inhibitors to enhance cancer immunotherapy using in vitro coculture assay and a mouse tumor model for immune checkpoint blockade (ICB) therapy. Results: We demonstrate that deficiency in LTO1, YAE1, or their downstream target ABCE1 impairs NMD, causes the overexpression of key regulators of MHC-I, including NLR family CARD domain containing 5 (NLRC5), interferon regulatory factor 1 (IRF1), and nuclear factor-kappa B (NFκB), which results in enhanced T cell activation and tumor cell killing in TCR-T models. Transcriptomic analyses reveal that the LTO1/YAE1 complex is frequently overexpressed in human cancers, where it negatively regulates MHC-I. Moreover, low doses of iron chelators inhibit NMD and enhance MHC-I expression, leading to improved recognition and activation of CD8 + T cells, thereby promoting antigen-specific killing and increasing the efficacy of TCR-T and ICB therapy. Conclusions: Collectively, our findings establish novel roles for the LTO1/YAE1 complex in regulating MHC-I expression via NMD. As MHC-I is crucial for antigen presentation and T cell activation, these results reveal a previously unappreciated link between NMD and tumor immunogenicity, with potential implications for cancer immunotherapies.